Role of Newer and Re-emerging Older Agents in the Treatment of Infections Caused by Carbapenem-resistant Enterobacteriaceae

Overview

Journal Virulence

Specialty Microbiology

Date 2016 Jul 8

PMID 27384881

Citations 57

Authors

Joshua T Thaden

Jason M Pogue

Keith S Kaye

Affiliations

Soon will be listed here.

Abstract

Antimicrobial resistance has been identified by the World Health Organization as "one of the three greatest threats to human health." Gram negative bacteria in particular drive this alarming trend. Carbapenem-resistant Enterobacteriaceae (CRE) such as Escherichia coli, Klebsiella pneumoniae, and Enterobacter species are of particular importance as they are associated with poor clinical outcomes and are common causes for a variety of infections including bacteremia, urinary tract infection, intra-abdominal infections and pneumonia. CRE are difficult to treat as carbapenem resistance is often accompanied by resistance to additional drug classes. For example, CRE may be extensively drug resistant or even pandrug resistant. Unfortunately, CRE infections have increased over the past 15 y while new and effective antibiotics have not kept pace. Recently, however, new agents have become available to help treat CRE infection, and several more are under development. This article reviews the efficacy, safety, and pharmacokinetic issues around 4 emerging agents to treat CRE - ceftazidime-avibactam, fosfomycin, tigecycline, and minocycline. In addition, an overview of agents in the antibiotic pipeline - meropenem-vaborbactam, imipenem-relebactam, plazomicin, and eravacycline is provided. More established agents, such as those in the polymyxin class and aminoglycoside class (other than the pipeline agent plazomicin), are not addressed here.

Citing Articles

Transient comparison of techniques to counter multi-drug resistant bacteria: prime modules in curation of bacterial infections.

Naveed M, Waseem M, Mahkdoom I, Ali N, Asif F, Hassan J Front Antibiot. 2025; 2():1309107.

PMID: 39816650 PMC: 11732137. DOI: 10.3389/frabi.2023.1309107.

Differences in microorganism profile in periprosthetic joint infections of the hip in patients affected by chronic kidney disease.

Stimolo D, Budin M, De Mauro D, Suero E, Gehrke T, Citak M J Orthop Traumatol. 2024; 25(1):67.

PMID: 39702802 PMC: 11659542. DOI: 10.1186/s10195-024-00806-x.

A systematic review of efficacy and safety of newer drugs approved from 2016 to 2023 for the treatment of complicated urinary tract infections.

Sivanandy P, Manirajan P, Wen Qi O, Teng Khai O, Chun Wei O, Wei Ying N Ann Med. 2024; 56(1):2403724.

PMID: 39530664 PMC: 11559027. DOI: 10.1080/07853890.2024.2403724.

In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates.

Lim T, Ho J, Teo J, Sim J, Tan S, Tan T Microorganisms. 2023; 11(9).

PMID: 37764002 PMC: 10534512. DOI: 10.3390/microorganisms11092158.

In vitro synergy screens of FDA-approved drugs reveal novel zidovudine- and azithromycin-based combinations with last-line antibiotics against Klebsiella pneumoniae.

Gomara-Lomero M, Lopez-Calleja A, Rezusta A, Ainsa J, Ramon-Garcia S Sci Rep. 2023; 13(1):14429.

PMID: 37660210 PMC: 10475115. DOI: 10.1038/s41598-023-39647-9.

References

Bulik C, Nicolau D . In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2010; 54(10):4112-5. PMC: 2944615. DOI: 10.1128/AAC.00026-10. View

Czaja C, Scholes D, Hooton T, Stamm W . Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis. 2007; 45(3):273-80. DOI: 10.1086/519268. View

Thaden J, Fowler V, Sexton D, Anderson D . Increasing Incidence of Extended-Spectrum β-Lactamase-Producing Escherichia coli in Community Hospitals throughout the Southeastern United States. Infect Control Hosp Epidemiol. 2015; 37(1):49-54. PMC: 4748740. DOI: 10.1017/ice.2015.239. View

Livermore D, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M . Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother. 2010; 66(1):48-53. DOI: 10.1093/jac/dkq408. View

Scaglione F, Cicchetti F, Demartini G, Arcidiacono M . Fosfomycin distribution in the lower urinary tract after administration of fosfomycin trometamol salt. Int J Clin Pharmacol Res. 1994; 14(3):107-9. View

Ritchie D, Garavaglia-Wilson A . A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014; 59 Suppl 6:S374-80. DOI: 10.1093/cid/ciu613. View

Lahiri S, Johnstone M, Ross P, McLaughlin R, Olivier N, Alm R . Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob Agents Chemother. 2014; 58(10):5704-13. PMC: 4187909. DOI: 10.1128/AAC.03057-14. View

Navarro-San Francisco C, Mora-Rillo M, Romero-Gomez M, Moreno-Ramos F, Rico-Nieto A, Ruiz-Carrascoso G . Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect. 2012; 19(2):E72-9. DOI: 10.1111/1469-0691.12091. View

Rogers J, Barnwell P, WATERMAN N, Austin F, Raff M . Clinical evaluation of intravenous minocycline. Int J Clin Pharmacol Biopharm. 1977; 15(4):194-8. View

10.

Sader H, Castanheira M, Flamm R, Mendes R, Farrell D, Jones R . Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013). Diagn Microbiol Infect Dis. 2015; 83(2):183-6. DOI: 10.1016/j.diagmicrobio.2015.06.011. View

11.

Kitchel B, Sundin D, Patel J . Regional dissemination of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2009; 53(10):4511-3. PMC: 2764151. DOI: 10.1128/AAC.00784-09. View

12.

Al-Hasan M, Eckel-Passow J, Baddour L . Impact of healthcare-associated acquisition on community-onset Gram-negative bloodstream infection: a population-based study: healthcare-associated Gram-negative BSI. Eur J Clin Microbiol Infect Dis. 2011; 31(6):1163-71. PMC: 3369543. DOI: 10.1007/s10096-011-1424-6. View

13.

Daikos G, Markogiannakis A . Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?. Clin Microbiol Infect. 2011; 17(8):1135-41. DOI: 10.1111/j.1469-0691.2011.03553.x. View

14.

Tumbarello M, Trecarichi E, De Rosa F, Giannella M, Giacobbe D, Bassetti M . Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015; 70(7):2133-43. DOI: 10.1093/jac/dkv086. View

15.

Peirano G, Ahmed-Bentley J, Woodford N, Pitout J . New Delhi metallo-beta-lactamase from traveler returning to Canada. Emerg Infect Dis. 2011; 17(2):242-4. PMC: 3204781. DOI: 10.3201/eid1702.101313. View

16.

Pogue J, Neelakanta A, Mynatt R, Sharma S, Lephart P, Kaye K . Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. Clin Infect Dis. 2014; 59 Suppl 6:S388-93. DOI: 10.1093/cid/ciu594. View

17.

Walkty A, Adam H, Baxter M, Denisuik A, Lagace-Wiens P, Karlowsky J . In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. Antimicrob Agents Chemother. 2014; 58(5):2554-63. PMC: 3993217. DOI: 10.1128/AAC.02744-13. View

18.

Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Quale J . Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City. Antimicrob Agents Chemother. 2015; 59(8):4856-60. PMC: 4505293. DOI: 10.1128/AAC.00843-15. View

19.

Sharma R, Park T, Moy S . Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms. Clin Ther. 2016; 38(3):431-44. DOI: 10.1016/j.clinthera.2016.01.018. View

20.

Tzouvelekis L, Markogiannakis A, Psichogiou M, Tassios P, Daikos G . Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012; 25(4):682-707. PMC: 3485753. DOI: 10.1128/CMR.05035-11. View